Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891552 | 0.90 | QDPR (0.59) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL23411537 | 0.90 | QDPR (0.59) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL30778341 | 0.89 | NAMPT (0.56) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL15157008 | 0.89 | NAMPT (0.56) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL15754653 | 0.88 | NAMPT (0.50) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL17303721 | 0.87 | NAMPT (0.49) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL17548155 | 0.87 | QDPR (0.56) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL19701840 | 0.87 | QDPR (0.56) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL19703158 | 0.87 | QDPR (0.56) | QDPRGRM1GRM5NAMPTPDK4 | |
| SCHEMBL18310124 | 0.86 | QDPR (0.57) | QDPRGRM1GRM5NAMPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | QDPR 2799/4885GRM1 2033/4885GRM5 2590/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | QDPR 1083/4885GRM1 4174/4885GRM5 2366/4885 |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | QDPR 3114/4885GRM1 1678/4885GRM5 2186/4885 |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ALK, BRAF, BMX | QDPR 1630/4885GRM1 774/4885GRM5 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.